Quoin Pharmaceuticals Ltd (QNRX)
6.74
-0.14 (2.03%)
Upcoming Events
Latest Headlines
Form D Quoin Pharmaceuticals
September 10, 2026 5:01 PM - SEC Filing
Form 8-K Quoin Pharmaceuticals For: Sep 08
September 10, 2026 4:06 PM - SEC Filing
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
September 10, 2026 8:30 AM - Globe NewsWire
Form 4 Quoin Pharmaceuticals, For: Aug 27 Filed by: LANGER DENNIS
August 28, 2026 6:41 PM - SEC Filing
Form 4 Quoin Pharmaceuticals, For: Aug 27 Filed by: Culverwell Anthony James
August 28, 2026 6:40 PM - SEC Filing
Form 8-K Quoin Pharmaceuticals, For: Aug 27
August 28, 2026 10:31 AM - SEC Filing
Quoin Pharmaceuticals raises up to $50M in private placement
August 28, 2026 6:00 AM - StreetInsider
Quoin Pharmaceuticals reports interim Phase 2/3 data for QRX003
August 28, 2026 6:00 AM - StreetInsider
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
August 28, 2026 6:00 AM - Globe NewsWire
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
August 28, 2026 6:00 AM - Globe NewsWire
Form 8-K Quoin Pharmaceuticals, For: Aug 20
August 20, 2026 4:19 PM - SEC Filing
Form 8-K Quoin Pharmaceuticals, For: Aug 14
August 14, 2026 4:10 PM - SEC Filing
Form 10-Q Quoin Pharmaceuticals, For: Jun 30
August 14, 2026 4:05 PM - SEC Filing
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 14, 2026 8:30 AM - Globe NewsWire
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
August 7, 2026 8:30 AM - Globe NewsWire
Form ARS Quoin Pharmaceuticals, For: Dec 31
July 16, 2026 7:35 AM - SEC Filing
Form DEF 14A Quoin Pharmaceuticals, For: Aug 20
July 16, 2026 7:31 AM - SEC Filing
Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease
July 9, 2026 8:30 AM - StreetInsider
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
July 9, 2026 8:30 AM - Globe NewsWire
Form PRE 14A Quoin Pharmaceuticals, For: Aug 20
July 6, 2026 5:21 PM - SEC Filing
Quoin Pharmaceuticals receives U.S. patent allowance for Netherton drug
June 30, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
June 30, 2026 8:30 AM - Globe NewsWire
Form 8-K Quoin Pharmaceuticals, For: Jun 23
June 23, 2026 4:16 PM - SEC Filing
FDA conditionally approves QYLEKI as brand name for Quoin drug
June 23, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
June 23, 2026 8:30 AM - Globe NewsWire
Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization
June 18, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
June 18, 2026 8:30 AM - StreetInsider
Full Article List
